Looks like a large bulk of this year's work is still on the pre-tox studies and manufacturing.
And as these kinks get worked out - later stages will progress much more smoothly and rapidly.
It's a long hump to get over - and longer than most here suspected, including myself.
If I hadn't averaged down a good deal from what I held back a few years ago, I would be somewhat more anxious. Luckily even at ~$3/share I'm sitting in a good position as the upcoming milestones are reached.
News 
Market Data 
Discover 
